19 February 2009: Reference is made to stock exchange notices of 16 January and 1 February 2009 regarding a rights issue in NorDiag ASA, as well as the prospectus dated 15 January 2009.

The new share capital in NorDiag ASA of NOK 12,065,168.60, as well as the issuance of A Warrants, B Warrants and C Warrants, is now registered in the Register of Business Enterprises and the rights issue is thus completed.

New Chairman of the Board
The completion of the rights issue implies that Robert V. Ahlgren takes up the position as the new Chairman of the Board of Directors in NorDiag ASA in accordance with the General Meeting's resolution 19 December 2008. The former Chairman of the Board Hans Hekland continues as an ordinary member of the Board of Directors.

Allotment of share options to the company's management, employees and key personnel
The General Meeting resolved on 19 December 2008 that the Board of Directors may neutralize the diluting effect of the rights issue by issuing up to 12,252,500 share options to the Company's management, employees, key personnel and to Robert V. Ahlgren in his position as Chairman of the Board of Directors. Conditional on and with effect from the date when the rights issue is completed, the Board of Directors resolved on 15 January 2009 to use the General Meeting's authorization to issue a sufficient and necessary number of options to existing option holders to neutralize the diluting effect of the rights issue, and that the strike price for new and existing options shall be set at NOK 0.50. Reference is made to stock exchange notice 15 January 2009.

Based on the Board of Directors' decision, new options are issued to existing option holders such as their total number of options corresponds to 2.2578 times the number of options held before the rights issue. For the Company's primary insiders this results in the following option allotment:

- CEO Mårten Wigstøl is allotted 628,900 new options, and thus holds a total of 1,128,900 options.
- CFO Tone Kvåle is allotted 377,340 new options, and thus holds a total of 677,340 options.
- Chief Accountant Stein Rune Kjelby is allotted 68,568 new options, and thus holds a total of 123,081 options.
- Sales & Marketing Director Dagfinn Strømme is allotted 188,670 new options, and thus holds a total of 338,670 options.
- Chief Scientific Officer Erik Hornes is allotted 628,900 new options, and thus holds a total of 1,128,900 options.
- President of NorDiag Inc Nancy Murphy is allotted 377,340 new options, and thus hold a total of 677,340 options.
- Sales Director Nordic Countries Jan Olav Wiksten is allotted 48,330 new options, and thus holds a total of 86,753 options.
- Chief Operation Officer Åse Wikshåland is allotted 188,670 new options, and thus holds a total of 338,670 options.
- QA Director Turid Engen is allotted 188,670 new options, and thus holds a total of 338,670 options.
- President of NorDiag AB Anders Holmberg is allotted 125,780 new options, and thus holds a total of 225,780 options.
- Accounting Clerk Monica Berg is allotted 43,978 new options, and thus holds a total of 78,942 options.
- Administration Consultant Elin Berge Flo is allotted 38,547 new options, and thus holds a total of 69,192 options.
- Senior VP Sales & Marketing Europa Roswitha Keller is allotted 677,340 options.
- Chairman of the Board Robert V. Ahlgren is allotted 225,780 options.

Contact:             
CEO Mårten Wigstøl      
Phone: +47 911 65775
or morten.wigstol@nordiag.com
                          
CFO Tone Kvåle               
Phone: +
47 915 19576
or tone.kvaale@nordiag.com

About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing automated solutions, instruments and tests, for diagnostic of infectious diseases and cancer. The Company`s core competence is isolation of bacterial and human DNA from difficult clinical samples, and the Company has established a solid market share in the Scandinavian market for sexually transmitted infections. The company has similar applications for Tuberculosis and MRSA. An application for respiratory pathogens is under development. NorDiag is also developing a test that shall contribute to early diagnosis of colorectal cancer. NorDiag was founded in 2003 and has its headquarters in Oslo - Norway. The Company has offices and laboratories in Bergen - Norway, Stockholm - Sweden and West Chester (PA) - USA. The group has 39 employees. NorDiag is listed on Oslo Stock Exchange with the ticker NORD. For further information - www.nordiag.com

Read the notice in Norwegian here